.STUDY EMPHASIZE.16 Oct 2024.
In the NIAGARA trial, the add-on of perioperative durvalumab to typical treatment for muscle-invasive bladder cancer strengthened event-free as well as in general survival, denoting a brand new procedure option for this condition.